Emerging PEGylated non-biologic drugs

Area of Science:

• Pharmaceutical Sciences
• Biotechnology
• Drug Delivery

Background:

• PEGylation, attaching polyethylene glycol (PEG), is a key technology for enhancing drug therapeutic value.
• Over 18 PEGylated products, including enzymes and proteins, are approved by the FDA.
• While biologics dominate, PEGylation is increasingly applied to non-biologic drugs.

Purpose of the Study:

• To review recent advancements in PEGylating non-biologic drugs.
• To highlight the development of PEGylated small organic molecules, synthetic peptides, and aptamers.
• To discuss the market potential and challenges of PEGylated non-biologic therapeutics.

Main Methods:

• Literature review of recent developments in PEGylation technology.
• Analysis of approved PEGylated products and those in clinical development.
• Examination of therapeutic applications and market trends for PEGylated drugs.

Main Results:

• PEGylation is expanding beyond biologic drugs to include small molecules, synthetic peptides, and aptamers.
• Numerous PEGylated non-biologic drugs, including anti-cancer agents and receptor agonists, are in development.
• PEGylation remains a commercially viable strategy for developing long-acting drug formulations.

Conclusions:

• PEGylation of non-biologic drugs represents a significant area of pharmaceutical innovation.
• Emerging PEGylated non-biologic drugs are poised to impact the market significantly.
• Despite some safety considerations, PEGylation continues to be a valuable approach for drug half-life extension.